Stock Analiz

BridgeBio Pharma, Inc. (BBIO) financials: revenue, earnings and cash flow

Fiscal 2017–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$725M, a net margin of -144.4%; the best year in this period was 2017 with -$31M.

Over the twelve months to September 30, 2026, revenue was $946M and net income -$592M.

Free cash flow was -$447M in fiscal 2025 and positive in 0 of the 9 years shown.

The diluted share count rose 526% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2019: $41M20192020: $8M20202021: $70M20212022: $78M20222023: $9M20232024: $222M20242025: $502M2025$502M
Net income
2017: -$31M172018: -$131M182019: -$261M192020: -$449M202021: -$563M212022: -$481M222023: -$643M232024: -$536M242025: -$725M25-$725M
Free cash flow
2017: -$41M172018: -$139M182019: -$256M192020: -$407M202021: -$511M212022: -$424M222023: -$529M232024: -$522M242025: -$447M25-$447M
EPS (diluted)
2017: $-1.00172018: $-2.12182019: $-2.48192020: $-3.80202021: $-3.90212022: $-3.26222023: $-3.95232024: $-2.88242025: $-3.7825$-3.78

Income statement

Fiscal yearTTM202520242023202220212020201920182017
Revenue$946M$502M$222M$9M$78M$70M$8M$41M——
Gross profit$892M$481M$218M$7M$74M$67M————
Operating income-$364M-$523M-$593M-$607M-$512M-$577M-$474M-$266M-$184M-$44M
Net income-$592M-$725M-$536M-$643M-$481M-$563M-$449M-$261M-$131M-$31M
EPS (diluted)$-3.03$-3.78$-2.88$-3.95$-3.26$-3.90$-3.80$-2.48$-2.12$-1.00
R&D$536M$452M$506M$456M$399M$451M$337M$210M$140M$31M
Revenue growth—+126.3%+2285.3%−88.0%+11.4%+745.1%−79.7%———

Cash flow

Fiscal yearTTM202520242023202220212020201920182017
Operating cash flow-$369M-$446M-$521M-$528M-$419M-$498M-$400M-$254M-$137M-$40M
Capital spending-$835000-$1M-$933000-$1M-$5M-$13M-$8M-$3M-$2M-$464000
Free cash flow-$370M-$447M-$522M-$529M-$424M-$511M-$407M-$256M-$139M-$41M
Dividends paid———————$997000—$1M
Buybacks$253M$48M$0$0$0$200M$75M———
Stock-based pay$152M$133M$96M$109M$92M$100M$58M$21M$6M$2M

Balance sheet

Fiscal yearTTM202520242023202220212020201920182017
Cash—$587M$681M$376M$428M$788M$607M$546M$436M$92M
Debt—$2.0B$447M$460M$447M$453M$112M$103M$55M—
Equity—-$2.1B-$1.5B-$1.4B-$1.3B-$870M$58M$408M$315M$86M
Total assets—$936M$919M$546M$623M$1.0B$704M$632M$465M—
Shares (diluted)196M192M186M163M147M144M118M105M62M31M

Margins and returns

Fiscal yearTTM202520242023202220212020201920182017
Gross margin94.3%95.8%98.2%73.7%95.6%95.5%————
Operating margin-38.5%-104.2%-267.2%-6528.7%-659.6%-827.1%-5752.0%-656.4%——
Net margin-62.6%-144.4%-241.4%-6913.9%-619.7%-806.9%-5439.7%-642.5%——
FCF margin-39.1%-89.0%-235.1%-5686.6%-546.5%-733.2%-4936.7%-631.7%——
ROIC——————-220.2%-41.1%-39.3%-40.4%
ROE—34.7%36.5%47.5%38.4%64.6%-774.9%-63.8%-41.5%-35.6%

Frequently asked questions

What is BridgeBio Pharma’s annual revenue?

$502M in fiscal 2025 and $946M over the twelve months to September 30, 2026.

How much profit does BridgeBio Pharma make?

Net income was -$725M in fiscal 2025 (net margin -144.4%).

Is BridgeBio Pharma’s revenue growing?

Yes: revenue rose 126.3% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.